Physician profile
David B Weinstein
NPI 1326142415
$5,747.02
in general payments reported to CMS, 2019-2025
37 companies · $899 in 2025
The $899 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $390 · 2021: $716 · 2022: $1,086 · 2023: $894 · 2024: $602 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $980.70 | 2019-2024 | Orilissa, Lo Loestrin Fe, Liletta |
| Mayne Pharma Commercial LLC | $699.58 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $412.36 | 2023-2025 | Gemtesa, Myfembree |
| Therapeuticsmd, INC. | $409.09 | 2019-2022 | |
| Pfizer INC. | $319.71 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $310.97 | 2019-2025 | |
| Astellas Pharma US INC | $301.98 | 2019-2025 | Veozah |
| Allergan, INC. | $256.76 | 2019-2020 | |
| Biogen, INC. | $228.98 | 2024-2025 | Zurzuvae |
| Exact Sciences Corporation | $217.43 | 2023-2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $178.85 | 2021-2022 | |
| Avion Pharmaceuticals | $178.27 | 2019-2022 | |
| Urovant Sciences INC | $135.12 | 2021-2022 | |
| Coopersurgical, INC. | $134.44 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Merck Sharp & Dohme LLC | $123.89 | 2019-2023 | Gardasil 9 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $95.46 | 2022 | |
| Evofem Biosciences, INC. | $92.39 | 2021-2022 | |
| Millicent US INC | $77.54 | 2025 | Intrarosa, Femlyv |
| Duchesnay USA Incorporated | $73.50 | 2019 | |
| Aspira Women'S Health INC | $73.31 | 2024-2025 | Ova1 |
| Mission Pharmacal Company | $53.86 | 2019-2020 | |
| Lupin INC. | $51.96 | 2019-2021 | |
| Daiichi Sankyo INC. | $47.16 | 2019 | |
| Vertical Pharmaceuticals, LLC | $46.46 | 2019 | |
| Agile Therapeutics, INC. | $35.66 | 2021-2022 | |
| Exeltis, USA INC. | $23.76 | 2025 | Slynd |
| Medicem INC. | $23.16 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.80 | 2019 | |
| Ascend Therapeutics US, LLC | $22.01 | 2021 | |
| Sanara Medtech INC. | $21.27 | 2021 | |
| Medline Industries LP | $20.46 | 2019 | |
| Coloplast Corp | $18.38 | 2019 | |
| Innovation Technologies INC | $17.12 | 2025 | Irrisept |
| Sage Therapeutics, LLC | $13.99 | 2021 | |
| Olympus America INC. | $12.99 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.43 | 2019 | |
| Meditrina | $4.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.